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Coronary Artery Disease in the Elderly 
Milton Alcaíno and Denisse Lama 
Cardiology Department, Hospital Dipreca, Santiago 
Chile 
1. Introduction 
Cardiovascular (CV) disease is the most frequent diagnosis in elderly people and it is the 
leading cause of death in both men and women older than 65 years of age. The high 
morbidity and mortality from cardiovascular disease warrant aggressive approaches to 
prevention and treatment that have been shown to be effective in older patients. Increased 
emphasis is being placed on preventive strategies for cardiovascular disease the elderly and 
improving the quality of care using therapies that were not designed for them. Historically 
physicians are prone to more conservative and use less aggressive therapies. Nevertheless, 
given their high-risk status, the elderly with heart disease are also a group that is very likely 
to experience improvements in clinical outcomes and functional status with 
revascularization. However, they are also more likely to experience procedural 
complications, owing to age-related physiological changes, frailty, and comorbidities. As 
such, the decision on when to pursue revascularization in elderly patients, and if so, how to 
revascularize, is complex. 
The limited representation of elderly patients in clinical trials has resulted in fewer data 
about the effectiveness of various strategies in this population. Moreover, the atypical 
clinical presentations of coronary artery disease (CAD) in elderly patients, and the 
consequent difficulty in diagnosis, have resulted in suboptimal implementation of treatment 
and secondary preventive measures by health care professionals. Increased investigation at 
both the basic level and clinical level is necessary to identify therapies that will benefit older 
patients on the basis of both the pathophysiology of age-related CV disease and the frequent 
presence of comorbid diseases. 
It is important to assess the risk of the patient individually to provide the best treatment 
strategy. Decisions regarding medical therapy versus revascularization; PCI or CABG 
should be based not only on symptoms, severity of CAD, left ventricular function but in the 
context of other comorbidities, lifestyle, projected life span, and preferences. In hospitals 
without PCI capability reperfusion therapy with thrombolytic should be considered, 
regarding thrombolytic drugs especially in very old patients, streptokinase should be 
considered. 
The purpose of this chapter is to explain the therapeutic approaches and considerations that 
must be taken when dealing with an elderly patient with CAD. To illustrate this we 
reviewed bibliographic databases such as medline and pubmed, with key words coronary 
artery disease, revascularization, thombolysis, coronary percutaneus intervention and 
elderly for our search.  
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Finally, we will demonstrate our experience in Chile with one of the few clinical trials in our 
country that includes the elderly as their main subjects of study, comparing different 
approaches of treatment towards CAD in this specific group of patients. 
2. Epidemiology 
The worldwide population of people 65 years of age and older are projected to increase to 
973 million or 12 percent by 2030 and to 20 percent of the population by 2050. Most 
definitions of elderly are based on chronological age. The World Health Organization uses 
60 years of age to define elderly whereas most classifications use the age of 65 years, but 
patients older than 75 years are more fragile. 
Cardiovascular disease is the most important cause of death in both men and women in this 
age group. More than 80 percent of all deaths attributable to cardiovascular diseases occur 
in people older than 65 years with approximately 60 percent of deaths in patients older than 
75 years old. High blood pressure, heart failure with preserved systolic function and 
multivessel disease are very common. Systolic blood pressure increases with aging, it occurs 
in one half to two thirds of people older than 65 years of age, and heart failure (HF) is the 
most frequent hospital discharge diagnosis among older patients. In addition, 
cardiovascular disease in the elderly usually is associated with other medical conditions 
given that eighty percent of people over 65 years old have at least one chronic medical 
condition, and half have at least two.  
The prevalence and severity of CAD increases with age in both men and women. A 
significant number of people older than the age of 60 years have significant CAD with 
increasing prevalence of left main or triple-vessel disease. Evidence of myocardial infarction 
(MI), abnormal echocardiogram, carotid intimal thickness, or abnormal ankle-brachial index 
have been detected in 22 percent of women and 33 percent of men aged 65 to 70 years and 
43 percent of women and 45 percent of men older than age 85 years. In addition, aging is 
associated to increased arterial stiffness and increased pulse pressure. There is an increase in 
fibrinogen, coagulation factors, platelet activity, increase in the levels of plasminogen 
activator inhibitor, resulting in impaired fibrinolysis. Inflammatory cytokines, endothelial 
dysfunction potentiate the development of atherosclerosis. 
3. Clinical presentation 
After the age of 80, a minority of patients complain of chest pain. Symptoms like angina are 
less frequent, ischaemia is more likely to be silent and pain description differs from the 
classic substernal pressure. Symptoms may be described primarily as dyspnea, shoulder or 
back pain, weakness, fatigue or epigastric discomfort. Some patients describe symptoms 
with effort, but others may not, because of limited physical activity, mental impairment or 
altered manifestations of pain caused by diabetes or age changes. Symptoms may occur at 
rest or during mental stress. Silent ischaemia has been reported in 20 to 50 percent of 
patients 65 years or older. Treadmill exercise testing can provide information in patients 
able to exercise but the specificity is reduced because of a high prevalence of resting ST-T 
abnormalities on the ECG of elderly patients. Exercise results can be enhanced by the use of 
modified low-intensity exercise protocols. Stress echocardiography or nuclear studies are 
very useful in case of exercise limitation or ECG alterations. The presence of coronary 
calcifications is not a clear predictor of cardiac events. There is a high prevalence of 
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hypertension, diabetes, obesity, and inactivity in the elderly and efforts in improving diet 
and activity levels, smoking cessation, treatment of hypertension and diabetes, are better 
than screening with vascular imaging studies in the asymptomatic elderly. 
4. Treatment 
4.1 Medical therapy 
In addition to life style changes and treatment of CAD risk factors, medical therapy is the 
main choice of treatment in most elderly patients, however revascularization, whether 
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) should 
not be neglected only because of age, and should be indicated as recommended by the 
guidelines. Aspirin, clopidogrel, nitrates, beta blockers, calcium antagonists, ACE inhibitors, 
statins and partial free fatty acid inhibitors have demonstrated benefits. Precautions must be 
taken regarding renal and hepatic function, hypotension and interaction with other 
medications. 
The U.S. Preventive Service Task Force recommends low doses of aspirin as primary 
prevention in men age 45 to 79 years old and women age 55 to 79 years old for prevention of 
myocardial infarction or stroke respectively when there are risks of MI or stroke but there is 
insufficient information regarding aspirin in primary prevention in the very elderly. For 
secondary prevention, there is strong evidence for the use of aspirin, given in low doses 
there is less risk of bleeding. 
Nitrates, beta blockers, ACE inhibitors and angiotensin receptor blockers can exacerbate 
hypotension or postural hypotension in the elderly. Also, B-blockers may produce central 
nervous system (CNS) effects and calcium channel blockers, especially the 
dihydropyridines, can produce edema which is more frequent in the older patient. 
Verapamil can exacerbate constipation. Both beta blockers and nondihydropyridine calcium 
channel blockers should be avoided in the presence of sick sinus node disease. 
Of the two early large primary prevention trials of lipid lowering with HMG CoA reductase 
inhibitors, one only enrolled men up to age 64 and the other had an upper age cutoff of 73 
years of age. In the ALLHAT cholesterol study, both the pravastatin and usual care groups 
had a substantial decrease in cholesterol levels. The 9,6 percent difference in cholesterol 
levels between the groups was insufficient to produce significant reductions in deaths 
(14,9% versus 15,3%) and produced only a small, non-significant decrease in the rates of 
heart attacks and strokes in the statin group relative to usual care (ALLHAT Collaborative 
Research Group, 2002). The Lipid Lowering Arm of the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT-LLA) tested the effects of lipid lowering in hypertensive patients 
up to age 79 years without increased lipids but with at least three additional CAD risk 
factors. ASCOT-LLA was stopped after 3.3 years because of a significant reduction in the 
primary end point of nonfatal MI and fatal CAD (Sever et al., 2003). Regarding secondary 
prevention, The Heart Protection Study demonstrated a 27% decrease in non-fatal MI and 
coronary death in patients older than 70 years of age. The Prospective Study of Pravastatin 
in the Elderly at Risk (PROSPER) a study with almost equal numbers of men and women 
aged 70 to 82 years who either had CAD or were at risk for cardiac events showed a 
significant reduction in mortality, nonfatal MI, and stroke (Shepherd et al., 2002). In 
summary, older patients should not be excluded from statin therapy, but caution must be 
taken in frail patients because of a higher risk of myopathy. 
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4.1.1 Considerations when prescribing medications in older patients 
 Knowledge of collateral effects of cardiovascular medications, specially hypotension, 
bradicardia or exacerbation electrical conductance defects. 
 Knowledge of non cardiac medications its effects and drug interaction with 
cardiovascular drugs. 
 Loading doses should be reduced. 
 Body surface area should be used to estimate dose (loading and maintenance). 
 Estimate glomerular filtration to guide dosing of medications. 
 Consider lower doses with hepatically cleared drugs. 
 Time between dosages should be adjusted. 
 Assess non adherence of medications. 
 Assess adequate financial coverage. 
4.2 Revascularization 
4.2.1 Cabg vs pci 
There is increased experience with both PCI and CABG in older patients. Half of all PCI and 
CABG procedures are performed in patients older than 65 years of age, with one third of 
coronary artery revascularization procedures performed in patients older than 70 years of age. 
The Bypass Angioplasty Revascularization Investigation (BARI) trial of patients with 
multivessel disease included 39% patients between the ages of 65 and 80 (BARI 
Investigators, 2007). It demonstrated that this group of patients had a higher early morbidity 
and mortality after CABG compared with PCI but greater angina relief and fewer repeat 
procedures after CABG. Stroke was more common after CABG (1.7% versus 0.2%, p = 
0.015). Heart failure or pulmonary edema were more common after PTCA (4.0 versus 1.3%, 
p = 0.011) and the 5-year survival rate was more than 80 percent for both procedures, with 
no difference between both treatments in non-diabetics but lower than in younger patients. 
The Northern New England Cardiovascular Disease Study Group included nearly 1693 
patients older than the age of 80 years who were treated for two or three vessel disease, 
found better in-hospital mortality and short-term survival for PCI versus CABG. For those 
surviving past 6 months, survival was better for patients who underwent CABG. PCI data 
were from bare metal stent implants, and CABG data were from on-pump procedures in 
more than 85 percent (Dacey et al, 2006). 
Elderly patients who require PCI are more likely to have complex, multivessel disease 
requiring multilession interventions, than their younger counterparts. Nonfatal 
complications with procedures increase with age. PCI is associated with a slightly less than 
1 percent risk of permanent stroke or coma, and CABG is associated with a 3 to 6 percent 
incidence of permanent stroke or coma in patients older than 75 years of age. Interventions 
on calcified plaques are associated with increased frequency of periprocedural 
complications, decreased procedural success rates and inadequate stent expansion and 
increased rates of restenosis. Tortuous and calcified vessels increase the difficulty of 
coronary device deployment and the risk of complications, including those with vascular 
access. Decreased vasodilatory response to nitroglycerin, increased plasma levels of 
activated coagulation factors and thrombin-antithrombin complexes are higher in older than 
in younger adults and platelet reactivity is also enhanced. These changes contribute to 
increased risk of acute thrombosis. 
As stated before, the metabolism of many drugs is reduced and renal drug clearance is 
also compromised with increasing age. The decline in renal function affects the 
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clearanceofanti-thrombotic drugs used in patients undergoing PCI, such as low-
molecular-weight heparin and glycoprotein (GP) IIb/ IIIa receptor inhibitors, and 
might, in part, explain the increased risk of bleeding seen when these agents are used in 
the elderly. Renal protection from contrast to prevent renal failure must be taken in 
consideration with pre and post procedure hydration with saline solution and the use of 
the lower dose of isosmolar contrast. 
Regarding CABG in the postoperative period, longer durations of ventilatory support, 
greater need for inotropic support and intraaortic balloon placement, greater incidence of 
atrial fibrillation, bleeding, renal failure, perioperative infarction, infection, stroke and 
delirium are seen in older patients compared with younger patients. The duration of 
disability and rehabilitation after procedures is usually longer, the risk of postoperative 
cognitive impairment in older patients detected with neuropsychological testing has been 
estimated as 25 to 50 percent after CABG. Depression is not uncommon as the need for 
prolonged hospitalization and home-assistance after discharge. The potential need for 
extended hospitalization, in-home assistance and depression after surgery should be 
assessed. Therefore there is an increase in mortality and morbidity especially during the 
first 30 days. 
Risk assessment should be evaluated with the Society of Thoracic Surgeons risk model (STS 
score) or (EuroSCORE). Nielssen et al, in 2006 published a study that compared these two 
risk algorithms for  CABG. Risk factors for all adult patients undergoing heart surgery at the 
University Hospital of Lund between 1996 and 2001 were collected prospectively at 
preoperative admission. The study included 4497 coronary artery bypass-only operations 
and the average age was 66.4 ± 9.3 years (range 31 to 90 years). In this study the EuroSCORE 
had a significantly better discriminatory power to predict 30-day mortality than the STS risk 
algorithm for patients undergoing coronary artery bypass. 
The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial 
(COURAGE) proved that the addition of PCI to optimum medical therapy did not reduce 
long-term rates of death, nonfatal MI, and hospitalization for ACS in patients with stable 
angina but showed that patients with severe angina who received PCI had greater 
improvements in angina symptoms and quality of life within the first 36 months than those 
who received medical therapy alone ( Boden et al, 2007). Among the patients over the age of 
65 years, a similar lack of benefit of PCI was shown (OR 1.10, 95% CI 0.83–1.46). In a 
subgroup analysis of 314 patients, studied with nuclear perfusion, PCI significantly reduced 
the rate of ischaemia in those with 10% or more of myocardium at risk. In this group, there 
was a lower risk of death and MI. An assessment of ischemic burden might be useful when 
deciding between invasive and medical management (Shaw et al, 2008). 
In the trial of Invasive versus Medical Therapy in Elderly Patients (TIME), patients 85 years 
and older, with chronic angina who were refractory to at least two antiangina medications, 
were randomly assigned to an invasive strategy (PCI or CABG) or to conservative medical 
therapy (TIME Investigators, 2001). The analysis demonstrated a decreased severity of angina 
in both groups, but death, non fatal MI or hospital admission for acute coronary syndrome 
was 19% in the invasive group versus 49% in the conservative group. In the Alberta Project for 
Outcomes Assessment in Coronary Heart Disease (APPROACH), in which the health status of 
21,573 patients with CAD treated with PCI, CABG surgery, or medical therapy was measured, 
among the 6,181 patients aged 70 years or older the improvements in health status observed 
with coronary revascularization was better at four years than in those patients treated 
medically, even in patients over 80 years of age (Graham et al, 2006). 
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ACC/AHA Coronary Artery Bypass Surgery and PCI Guidelines conclude that age alone 
should not be used as the sole criterion when considering revascularization procedures. 
Individualized prognostic information based on multiple clinical factors and respect for 
patient preference in the decision-making process has a clear role. 
5. Acute coronary syndromes 
About 60 percent of hospital admissions for acute myocardial infarction (AMI) occur in 
people older than 65 years, and account for approximately 85 percent of deaths caused by 
AMI. With increasing age, the gender composition of patients presenting with AMI changes 
from predominantly men in the middle age, to an equal number of men and women and a 
majority of women in patients older than 80 years of age. Mortality is higher in older 
women than in older men with AMI, as are adverse outcomes with thrombolytics, and 
glycoprotein (GP) IIb/IIIa inhibitors. As age increases, there are more patients with 
functional limitation, heart failure, prior coronary disease, renal insufficiency and patients 
with prior revascularization. Fewer older patients present with chest pain or ST elevation on 
ECG within 6 hours of symptom onset. 
5.1 Thrombolysis 
Most randomized clinical trials of thrombolysis have enrolled few patients older than 75 years 
of age. In a study of 14,341 of Medicare patients older than 65 years with ST elevation MI or 
left bundle bunch block, treated with thrombolytics there was a significant reduction of 
mortality at one year, but with 1.5 rate of intracranial hemorrhage. The Fibrinolytics Therapy 
Trialists´ found a 15% percent reduction in mortality in patients older than 65 years, and there 
were 34 lives saved per 1000 patients. This result was more effective than in younger patients 
in whom 11 lives were saved per 1000 patients. Some studies that include patients up to 75 
years of age have demonstrated that fibrinolytic, antiplatelet, and antithrombin therapy is 
associated with a survival advantage compared with placebo that may be similar to than that 
seen in younger patients. The Global Utilization of Streptokinase and Tissue plasminogen 
activator for Ocluded coronary arteries-I (GUSTO I) found a significant absolute reduction in 
mortality with thrombolysis, specially with plasminogen activator in patients 65 to 85 years of 
age. In patients older than 85 there was a beneficial trend with streptokinase. Finally, in a 
registry of Swedish Hearts Intensive Care Admissions, in a group of 6,891 patients 75 years 
and older, fibrolytic therapy was associated with a 13% relative reduction in the composite of 
mortality and cerebral bleeding complications at one year. Complication of minor and major 
bleeding, intracranial bleeding and transfusion rates are higher in older patients compared 
with younger patients with all agents and some subgroups may not have an overall benefit 
from use of thrombolytics. Those with high risk for ICH include patients older than 75 years, 
women, African Americans, small size, prior stroke, systolic blood pressure >160 mm Hg. 
Fibrin-specific agents such as tissue plasminogen activator are also associated with increased 
stroke risk caused by ICH in the older than 75 year age group. Improper dosing of antiplatelet, 
antithrombin agents or combinations with low-molecular-weight heparins or GP IIB/IIIa 
inhibitors increase as well the risk of bleeding. Even with dose adjustments, however, the risk 
of bleeding appears increased in older patients. 
5.2 Antithrombotic agents 
Trial data shows that aspirin reduces mortality in patients older than 70 years and is 
recommended for routine administration to older patients with acute MI, although older 
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patients have been less likely to receive aspirin than younger patients in routine clinical 
practice. The addition of clopidogrel to aspirin reduces major events, with similar absolute 
reductions in patients younger and older than 65 years. In the Clopidogrel and Metoprolol 
in Myocardial Infarction Trial (COMMIT), a chinese megatrial with almost 46,000 MI 
patients, with 11,934 patients older than 70, in which half of the patients were treated with 
clopidogrel and the other half with placebo, there was a 9% reduction in the composite end 
point of death, reinfarction and stroke without an increase in serious bleeding. It also 
showed a significant reduction in mortality in the patients treated with clopidogrel 
(COMMIT Collaborative Group, 2005). Patients were treated with 75 mg. of clopidogrel 
without the 300 milligrams loading dose. Low- dose of aspirin (< 100mg.) should be used 
when combined with clopidogrel. Prasugrel is not recomended in patients over 75 years and 
there is not enough information on the safety about ticagrelor. GP IIb/IIIa inhibitors appear 
efficacious in older patients but in patients over age 75 years when given in combination 
with thrombolytics there is an increased risk of bleeding. Bleeding is about twofold greater 
in older patients undergoing PCI who receive GP IIb/IIIa inhibitors compared with patients 
who do not, with intracranial bleeding as the most common site of fatal bleeds.  
Antiplatelet and antithrombin agents have narrow therapeutic windows dosing should be 
based on weight and renal function. Prospective observational analyses have shown that 
more than 40 percent of patients with acute coronary syndromes receiving unfractionated 
heparin, low-molecular-weight heparin, or GP IIb/IIIa inhibitors receive at least one dose in 
excess of guidelines. Factors associated with excess dosing were older age, female sex, renal 
insufficiency, low body weight, diabetes mellitus, and congestive HF. Bleeding increased 
relative to the degree of excess dose and to the number of agents administered in excess. 
Mortality is higher and length of hospital stay is longer in patients administered excess 
dosing and there is a close relation between bleeding and mortality. Women had twofold 
higher rates of major bleeding than men and are three times more likely to receive excess GP 
IIb/IIIa doses than men. Approximately 25 percent of the bleeding risk was attributable to 
excess dosing in women versus 4.4 percent in men. A randomized, controlled clinical trial 
for treatment of acute MI with PCI with eptifibatide administration has also reported 
increased bleeding resulting from lack of dose adjustment for reduced renal function 
(Kirtane et al, 2006). Fondaparinux and bivalirudin have shown less risk of bleeding in 
patients with ST-elevation MI (STEMI) and non-STEMI, including the elderly.  
Primary angioplasty in experienced centers is associated with improved outcomes 
compared with thrombolytic strategies in elderly patients with STEMI. Even when mortality 
is reduced with primary PCI compared with thrombolytic therapy, in-hospital mortality of 
patients older than the age of 75 years is estimated to be fivefold higher than patients 
younger than 75 years, and 1-year mortality is 7-fold greater. Achieving revascularization 
within 90 minutes is less likely in older patients with delays in diagnosis and/or transport 
to experienced centers. Acute procedural success rates are also somewhat lower than in 
younger MI populations, there are increased risk of bleeding, complications including those 
at the access site, increased transfusion requirements and contrast-mediated renal 
dysfunction. However, PCI is preferred to fibrinolysis as a reperfusion option for elderly 
patients who experience STEMI. 
The Global use of strategies to open Occluded Coronary Arteries (GUSTO) IIb trial was one 
of the first to report that PCI is superior to fibrinolysis among all age groups, and in 
particular that this strategy has the greatest benefit in the elderly, when all age groups are 
compared (Angioplasty Substudy Investigators, 1997). The National Registry of Myocardial 
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Infarction (NRMI)-2, evaluated 38,787 patients in which the treatment was performed within 
12 hours of onset symptoms with either an intravenous thrombolytic agent or PCI. Of these, 
10,2% were treated with streptokinase or anistreplase, 77,1% were treated with alteplase and 
12,7% underwent primary PCI. In patients with STEMI who were aged 75 years, this study 
demonstrated that there was a lower risk of the combined end points of death and nonfatal 
stroke with primary PCI than with fibrinolysis, owing primarily to a higher rate of 
intracranial bleeding (2.5%) observed in the fibrinolysis group (Tiefenbrunn, 1998). In the 
Senior Primary Angioplasty in Myocardial Infarction (Senior PAMI) study, PCI was 
superior to thrombolytic therapy from ages 65 to 79 with no advantage of primary PCI over 
thrombolysis in those older than 80 years of age (Grines, 2005).In the observational setting, 
the Global Registry of Acute Coronary Events (GRACE) showed lower adjusted in-hospital 
mortality (or 0.62, 95% Ci 0.39–0.96) for primary PCI compared with fibrinolysis among 
2,975 patients with STEMI who were aged ≥70 years (Mehta, et al, 2004). The Tratamiento 
del Infarto Agudo del Miocardio en Ancianos (TRIANA) compared primary PCI and 
fibrinolysis in very old patients (mean age 81). It enrolled 266 patients, 134 allocated to PCI 
and 132 to fibrinolysis, both groups were well balanced in baseline characteristics, and it 
demonstrated that recurrent ischemia was less common in PCI-treated patients (0.8 vs. 9.7%, 
P< 0,001). No differences were found in major bleeds. A pooled analysis with two previous 
reperfusion trials performed in older patients showed an advantage of PCI over fibrinolysis 
in reducing death, re-infarction, or stroke at 30 days (Bueno, et al, 2010). Finally, in a meta-
analysis of 22 randomized trials (n= 6,763) evaluating the effects of primary PCI versus 
fibrinolysis, de Boer et al showed a mortality reduction favoring primary PCI in all age 
strata, as well as reductions in the risk of repeat MI and stroke. 
Regarding non STEMI, it is the most frequent manifestation of CAD and represents the largest 
group of patients undergoing PCI. Despite the advances in medical and interventional 
treatments, the mortality and morbidity remain high and equivalent to patients with STEMI 
after the initial month. The ultimate goals of angiography and revascularization are mainly 
twofold: symptom relief, and improvement of prognosis in the short and long term. Different 
trials have shown that an invasive strategy reduces ischaemic endpoints mainly by reducing 
severe recurrent ischaemia and the clinical need for revascularization. The most recent meta-
analysis of 3 randomized trials with a follow up of 5 years, showed a 19 % relative reduction in 
non fatal MI and death. This difference was mainly driven by reduction in MI. In these trials 
between 12,5% to 18,8% of the patients were over 75 years old, most of them in the high risk 
group, in whom the invasive therapy had the greatest effect. (Fox, 2010) 
6. Drug eluting versus bare metal stents 
Randomized controlled trials and pooled analyses of randomized trials in which drug eluting 
stents (DES) and bare metal stents (BMS) have been compared demonstrate similar acute and 
intermediate survival and MI outcomes among nonelderly patients. Elderly patients enrolled 
in these trials has been small and no dedicated randomized comparison trial of DES to BMS 
has been performed among patients aged >65 years. In a study of 71,965 elderly patients 
(mean age 75 years) undergoing PCI, in those in whom DES were used, there was lower 
adjusted mortality (HR 0.83, 95% Ci 0.81–0.86) than contemporary controls undergoing BMS 
implantation. DES-treated patients were also less likely than controls to undergo 
revascularization procedures within 2 years after PCI and had fewer hospitalizations for MI. In 
an analysis of 262,700 Medicare patients (mean age 73 years) treated at 650 hospitals from 2004 
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to 2006, recipients of DES (83% of whom were aged over 65 years) had lower risk adjusted 
mortality (HR 0.75, 95% Ci 0.72–0.79) and risk of MI (HR 0.77, 95% Ci 0.72–0.81) than BMS-
treated patients, but had minimal differences in rates of repeat revascularization or bleeding. 
7. Our experience in chile 
We performed a study randomised, retrospective comparing DES versus BMS in elderly 
patients 75 years and older who underwent PCI. The clinical setting was STEMI in 40 
percent of patients, non STEMI in 25 percent, stable angina in 24 percent and silent 
ischaemia in 11 percent. The purpose of this study was to determine whether the use of DES 
was associated with less mortality, MI (fatal and non fatal), angina and hospitalization of 
cardiac causes. One hundred and forty six patients were analyzed in which DES and BMS 
were implanted between the years 2003 and 2007, with a median follow up of 5.2 years. 
Twenty nine patients were selected in the DES group and 26 in the BMS group. The groups 
were comparable according to age, gender, risk factors, symptoms, ejection fraction, number 
of vessels affected and number of stents implanted (Table 1). 
 
CHARACTERISTICS BMS DES P 
Nº OF PATIENTS 26 29  
PREVIOUS MI 6 6 NS* 
DIABETES 9 14 NS* 
HYPERTENSION 23 20 NS* 
HIGH CHOLESTEROL 14 20 NS* 
AGE 79,8 79,4 NS** 
MALE 15 14 NS* 
TOBACCO 2 3 NS* 
PREVIOUS PCI 4 9 NS* 
1 VESSEL DISEASE 12 13 NS* 
2 VESSELS DISEASE 5 6 NS* 
3 VESSELS DISEASE 9 10 NS* 
LVEF > 50% 17 16 NS* 
1 VESSEL TREATED 18 20 NS* 
MORE THAN 1 VESSEL 
TREATED 8 9 NS* 
* Chi-squared ** T- Student 
NS: statistically non significant LVEF: left ventricular ejection fraction 
Table 1. Baseline Characteristics 
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Both groups were compared according to global mortality, mortality of cardiac disease, 
presence of angina, MI and hospitalizations because of a cardiac disease. As shown in table 
2, in this group of elderly patients in which a DES was implanted there were no differences 
in global mortality, MI and angina when compared to the group of patients in which a BMS 
was implanted. However, there was statistical significant less hospitalization because of 
cardiac disease and a tendency to less mortality because of cardiac disease. 
 
 BMS DES P 
Nº of patients 26 (100%) 29 (100%) 0,9767 
Global Mortality 9 (34,6%) 11 (38%) 0, 8117 
Mortality of Cardiac disease 7 (26,4%) 3(10%) 0,98 
Angina 3 (11, 5 %) 4 (13, 7 %) NS 
MI 2 (7, 6 %) 3 (10, 3 %) NS 
Hospitalization because of 
cardiac disease 
9 (34, 6%) 5 (17, 2%) 0,0001 
Table 2. Results 
8. Rehabilitation 
The feasibility and improvement with intensive exercise interventions have been shown for 
both the frailest elderly residing in the community as well as in the nursing home. The 
Cardiac Rehabilitation in Advanced Age (CR-AGE) trial compared hospital-based cardiac 
rehabilitation with home-based cardiac rehabilitation in cognitively intact patients from ages 
46 to 86 with recent MI (Marchionni et al., 2003). Similar improvement in total work capacity 
and health-related quality of life was seen with home-based rehabilitation compared with 
hospital-based rehabilitation in all age groups without improvement in the control group. 
The improvement, however, was somewhat smaller in the group older than age 75. Benefits 
decreased over time after hospital rehabilitation but were maintained with home cardiac 
rehabilitation. Complications were similar across groups, whereas costs were lower in the 
home rehabilitation group. 
In summary, what to consider when approaching to the older patient with CAD: 
1. Morbidity and mortality in the elderly with CAD and CAD treated medically or with 
revascularization increases with age, especially in patients older than age 75 years. 
2. Special care must be taken regarding medications, dose, collateral effects, drug 
interactions and interaction with other comorbidities. 
3. Clinically recognized CAD or heart failure confer the greatest risk for cardiac death and 
warrant aggressive secondary prevention strategies. 
4. In STEMI patients 
 In hospitals where direct PCI can be performed rapidly by experienced operators, 
PCI has an advantage over thrombolysis. 
 In hospitals without PCI capability reperfusion therapy with thrombolytic should 
be considered, regarding thrombolytic drugs especially in very old patients, 
streptokinase should be considered. 
 Avoid combinations of GP IIb/IIIa inhibitors with thrombolytics. In case of low 
molecular heparins and thrombolytics, lower doses as recommended can be used. 
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 The use of antiplatelet and antithrombotic drugs is recommended according to the 
guidelines but a careful evaluation of the bleeding risk should be taken. 
 For non STEMI patients the same care with antiplatelets and antithrombotic drugs 
must be taken and the same recommendations of the guidelines regarding invasive 
or conservative approach must be taken. 
5. Decisions regarding medical therapy versus revascularization: PCI or CABG should be 
based not only on symptoms, severity of CAD, left ventricular function but in the 
context of other comorbidities, lifestyle, projected life span, and preferences. 
6. In case of PCI the patient and family must be aware of the risks but some are less 
explained by the physician, especially lower success, renal failure, prolonged 
hospitalization and bleeding. The radial approach should be preferred in order to 
diminish this last complication. 
7. In case of CABG prolonged hospitalization because respiratory, renal, central nervous 
system or infectious conditions and special home care should be emphasized. 
9. Conclusion 
CAD in the elderly is more severe and is accompanied by a high rate of comorbidities. There 
are a few trials that include a significant number of older patients, therefore there is little 
information on how to optimize treatment in this age group. There are age-associated 
pathophysiological changes as well different comorbidities. Physicians tend to be more 
conservative and use less aggressive therapies, although it has been proven that these patients 
have greater benefits with aggressive therapy but also complications are more common. The 
elderly with CAD are also a group that is very likely to experience improvements in clinical 
outcomes and functional status with revascularization. The decision on when to perform 
revascularization in elderly patients and how to revascularize, is difficult. More than one in 
five patients treated with percutaneous coronary intervention (PCI) are aged ≥75 years and the 
proportion of elderly individuals in the population is growing. Although a slight advantage of 
surgical over percutaneous revascularization might exist for elderly patients with multivessel 
coronary disease, surgical revascularization should remain an option for a selected population 
of elderly patients with few comorbidities. 
10. Future directions 
Increasing emphasis is being placed on preventive strategies for CAD in older patients and 
improving the quality of care using current therapies that were not designed for the elderly. A 
major limitation is the lack of understanding of the mechanisms underlying many age-related 
cardiovascular changes or diseases. Increased investigation at both the basic level and clinical 
level is necessary to identify therapies that will benefit older patients on the basis of both the 
pathophysiology of age-related CV disease and the frequent presence of comorbid diseases. 
Caring for patients near the end of their lives is different than caring for patients with longer 
life expectancies. Research and training will be necessary to achieve coordinated care for the 
older patient, and both medical and social factors must be considered to provide optimal care. 
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